

Management of 5-Fluorouracil Treatment using Therapeutic Drug Monitoring (TDM)

Edward Chu, MD

University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center
Pittsburgh, PA, USA

Scope of the lecture:

This lecture will review the role of therapeutic drug monitoring (TDM) of the fluoropyrimidine 5-fluorouracil (5-FU) with respect to the treatment of colorectal cancer.

Learning objectives:

1. Review the traditional approach to dosing of the fluoropyrimidine 5-FU.
2. Review the oncology drugs where TDM is currently being practiced.
3. Review retrospective clinical studies where pharmacokinetic (PK)-based dose adjustment was employed for 5-FU-based chemotherapy regimens
4. Review prospective clinical studies where PK-based dose adjustment was employed for 5-FU-based chemotherapy regimens.
5. Review the different assay systems to quantitate 5-FU plasma levels.
6. Review other methods to determine 5-FU dosing.
7. Review the pharmacoeconomics of 5-FU TDM.
8. Review the recommendations on TDM of 5-FU in patients with colon cancer and other human cancers.

Extended Abstract:

For over 50 years, 5-FU has played a critical role in the systemic chemotherapy of cancer patients. 5-FU serves as the main backbone of combination chemotherapy for patients with colorectal cancer (CRC) in both the adjuvant and metastatic disease settings. This presentation will review the current status of 5-FU therapeutic drug monitoring (TDM) and discuss its potential role in the clinical practice setting.

5-FU dosing has been typically determined by using body surface area (BSA). However, it is now well-established that BSA-based 5-FU dosing is correlated with a wide variation of 5-FU systemic exposure. Pharmacokinetic (PK) studies of 5-FU systemic exposure have shown a wide range of interpatient variation of 5-FU plasma drug levels. Over the past 30 years, increasing efforts have been placed on optimizing 5-FU dosing with the main goals of increasing antitumor efficacy while reducing drug-associated toxicity. There is growing evidence to show that 5-FU dosing based on plasma 5-FU drug level is feasible and that 5-FU TDM can improve clinical outcomes by improving efficacy of 5-FU-based combination regimens and reducing toxicities.

The clinical activity of 5-FU is modest at standard doses, and in general, dosing is limited by the safety profile, with myelosuppression and gastrointestinal toxicity being the most commonly observed side effects. Various strategies have been developed to enhance the clinical activity of 5-FU, such as biochemical modulation, alterations in scheduling of administration, and the use of oral chemotherapy. Studies that have shown an association between plasma concentration with toxicity and clinical efficacy have shown that pharmacokinetically-guided dose adjustments can substantially improve the therapeutic index of 5-FU treatment. These studies have shown that only 20% to 30% of patients treated with a 5-FU-based regimen have 5-FU levels that are in the appropriate therapeutic range—approximately 40% to 60% of patients are under-dosed and 10% to 20% of patients are over-dosed. To date, 5-FU drug testing has not been widely used due to the lack of a simple, fast, and inexpensive method. Although 5-FU pharmacokinetic studies using cell-based and physical detection methods have been conducted since the mid-1960s, the application of 5-FU pharmacokinetic monitoring to clinical practice has become more realistic and practical since 5-FU administration via infusion schedules evolved to become the standard of care over the past 5-8 years. Recent advances in testing based on liquid chromatography-tandem mass spectroscopy and a nanoparticle antibody-based immunoassay for 5-FU may now allow for routine monitoring of 5-FU in clinical practice. We review the data on pharmacokinetically-guided dose adjustment of 5-FU and discuss the potential of this approach to advance therapeutic outcomes.

Clinical studies that were conducted during the past 20 years have demonstrated reduced toxicity and improved clinical outcomes with pharmacokinetic dose management. These pharmacokinetically-guided studies have identified an optimal target therapeutic range for 5-FU and have recommended dose adjustment algorithms to bring plasma concentrations into the optimal range. A number of retrospective and prospective clinical studies have shown that many patients who are currently being treated with 5-FU are not being given the appropriate doses to achieve optimal plasma concentration. Of note, only 20% to 30% of patients are treated in the appropriate AUC range, approximately 40% to 60% of patients are being underdosed, and 10% to 20% of patients are overdosed. Studies that have shown associations between 5-FU plasma concentration and toxicity and clinical efficacy demonstrated that pharmacokinetically-guided dose adjustments substantially improve these biological effects, which are associated with 5-FU therapy. While 5-FU monitoring has been widely used in

various countries in Europe, such as France and Germany, it has not been widely in the United States.

Over the last four decades, 5-FU TDM has made significant progress, and there is now a validated algorithm of 5-FU dose adjustment based on plasma 5-FU levels to reduce toxicity and improve efficacy of 5-FU. Several methods have been developed to directly measure 5-FU drug levels in peripheral blood, including HPLC, GC-MS, and LC-MS/MS. More recently, an immunoassay has been developed that can accurately and sensitively measure 5-FU. This test has significant logistical advantages over traditional HPLC and LC-MS/MS methods. Evidence is also emerging to show that the use of 5-FU TDM results in significant cost savings with quality adjusted life-year (QALY) gain for FOLFOX chemotherapy in patients with mCRC. Finally, in this era of precision medicine, 5-FU TDM should be considered a clinically relevant and central element of personalized medicine in the everyday care of cancer patients.

This presentation will show that 5-FU TDM is feasible and PK-based dosing can significantly improve clinical outcomes by reducing toxicities and improving efficacy. In addition, this presentation will review and discuss the formal recommendations as to how to optimize 5-FU TDM in the treatment of colorectal cancer and other human cancers.

References:

1. Saif MW, Choma A, Salamone SJ, Chu E (2009). Pharmacokinetically-guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. *J Natl Cancer Inst.* 101:1543-52. PMID: 19841331
2. Lee JJ, Beumer JH, Chu E (2016). Therapeutic drug monitoring of 5-fluorouracil. *Cancer Chemother Pharmacol.* 78:447-64. PMID: 27217046.
3. Beumer JH (2013). Without therapeutic drug monitoring, there is no personalized cancer care. *Clin Pharmacol Ther* 93:228-230
4. Bardin C, Veal G, Paci A, Chatelut E, Astier A, Leveque D, Widmer N, Beijnen J (2014). Therapeutic drug monitoring in cancer--are we missing a trick? *Eur J Cancer* 50:2005-2009
5. Beumer JH, Chu E, Salamone SJ (2012). Body-surface area-based chemotherapy dosing: appropriate in the 21st century? *J Clin Oncol* 30:3896-3897

6. Milano G, Etienne MC, Cassuto-Viguier E, Thyss A, Santini J, Frenay M, Renee N, Schneider M, Demard F (1992). Influence of sex and age on fluorouracil clearance. *J Clin Oncol* 10:1171-1175
7. Gamelin E, Boisdron-Celle M, Guerin-Meyer V, Delva R, Lortholary A, Genevieve F, Larra F, Ifrah N, Robert J (1999). Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. *J Clin Oncol* 17:1105
8. van Kuilenburg AB, Maring JG (2013). Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients. *Pharmacogenomics* 14:799-811.
9. Thyss A, Milano G, Renee N, Vallicioni J, Schneider M, Demard F (1986). Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. *Cancer Chemother Pharmacol* 16:64-66.
10. Yoshida T, Araki E, Iigo M, Fujii T, Yoshino M, Shimada Y, Saito D, Tajiri H, Yamaguchi H, Yoshida S, Yoshino M, Ohkura H, Yoshimori M, Okazaki N (1990). Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer. *Cancer Chemother Pharmacol* 26:352-354.
11. Goldstein DA, Chen Q, Howard DH, Lipscomb J, Ayer T, Harvey D, El-Rayes BF, Flowers C (2014). Cost-effectiveness analysis of pharmacokinetic-guided (PK) 5-fluorouracil (5FU) when combined with leucovorin and oxaliplatin (FOLFOX) chemotherapy for metastatic colorectal cancer (mCRC). *J Clin Oncol* 32:6527.
12. Goldstein DA, Chen Q, Ayer T, Howard DH, Lipscomb J, Harvey RD, El-Rayes BF, Flowers CR (2014). Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer. *Clin Colorectal Cancer* 13:219-225.
13. van Staveren MC, Guchelaar HJ, van Kuilenburg AB, Gelderblom H, Maring JG (2013). Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency. *Pharmacogenomics J* 13:389-395.
14. Yen JL, McLeod HL (2007). Should DPD analysis be required prior to prescribing fluoropyrimidines? *Eur J Cancer* 43:1011-1016.
15. Goel G, Lee JJ (2014). Pharmacokinetically Guided Dose Adjustment of 5-FU-A Critical Element Toward Personalized Medicine. *Clin Colorectal Cancer* 13:1-2.
16. Hillcoat BL, McCulloch PB, Figueredo AT, Ehsan MH, Rosenfeld JM (1978). Clinical response and plasma levels of 5-fluorouracil in patients

with colonic cancer treated by drug infusion. *Br J Cancer* 38:719-724.

17. van Groenigen CJ, Pinedo HM, Heddes J, Kok RM, de Jong AP, Wattel E, Peters GJ, Lankelma J (1988). Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. *Cancer Res* 48:6956-6961.
18. Trump DL, Egorin MJ, Forrest A, Willson JK, Remick S, Tutsch, KD (1991). Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. *J Clin Oncol* 9:2027-2035.
19. Milano G, Etienne MC, Renee N, Thyss A, Schneider M, Ramaioli A, Demard F (1994). Relationship between fluorouracil systemic exposure and tumor response and patient survival. *J Clin Oncol* 12:1291-1295.
20. Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, Maillart PJ, Goudier MJ, Burtin PC, Delva RG, Lortholary AH, Gesta PH, Larra FG (1996). Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. *Cancer* 77:441-451.
21. Saam J, Critchfield GC, Hamilton SA, Roa BB, Wenstrup RJ, Kaldate RR (2011). Body surface area-based dosing of 5-fluorouracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens. *Clin Colorectal Cancer* 10:203-206.
22. Kline CL, Sheikh HS, Scicchitano A, Gingrich R, Beachler C, Finnberg NK, Liao J, Sivik J, El-Deiry WS (2011). Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients. *Cancer Biol Ther* 12:557-568.
23. Kaldate RR, Haregewoin A, Grier CE, Hamilton SA, McLeod HL (2012). Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6. *Oncologist* 17:296-302.
24. Gamelin E, Boisdron-Celle M, Delva R, Regimbeau C, Cailleux PE, Alleaume C, Maillet ML, Goudier MJ, Sire M, Person-Joly MC, Maigre M, Maillart P, Fety R, Burtin P, Lortholary A, Dumesnil Y, Picon L, Geslin J, Gesta P, Danquechin-Dorval E, Larra F, Robert J (1998). Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. *J Clin Oncol* 16:1470-1478.
25. Kline CL, Schicchitano A, Zhu J, Beachler C, Sheikh H, Harvey HA, Mackley HB, McKenna K, Staveley-O'Carroll K, Poritz L, Messaris E, Stewart D, Sivik J, El-Deiry WS (2014). Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early-

or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens. *Clin Colorectal Cancer* 13:119-126.

26. Braiteh FS, Salamone SJ, Li Y, Courtney JB, Duda M, Diamond S, Miller MC (2014). Pharmacokinetic (PK)-guided optimization of 5-fluorouracil (5FU) exposure in colorectal cancer (CRC) patients: U.S.-based clinical practices experience. *J Clin Oncol* 32:3574.
27. Santini J, Milano G, Thyss A, Renee N, Viens P, Ayela P, Schneider M, Demard F (1989). 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. *Br J Cancer* 59:287-290.
28. Fety R, Rolland F, Barberi-Heyob M, Hardouin A, Champion L, Conroy T, Merlin JL, Riviere A, Perrocheau G, Etienne MC, Milano G (1998). Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. *Clin Cancer Res* 4:2039-2045.
29. Ychou M, Duffour J, Kramar A, Debrigode C, Gourgou S, Bressolle F, Pinguet F (2003). Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. *Cancer Chemother Pharmacol* 52:282-290
30. Gamelin E, Delva R, Jacob J, Merrouche Y, Raoul JL, Pezet D, Dorval E, Piot G, Morel A, Boisdron-Celle M (2008). Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. *J Clin Oncol* 26:2099-2105.
31. Capitain O, Asevoaia A, Boisdron-Celle M, Poirier AL, Morel A, Gamelin E (2012). Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. *Clin Colorectal Cancer* 11:263-267.
32. Patel JN, O'Neil BH, McLeod HL, Sherrill GB, Olijade O, Inzerillo JJ, Atluri P, Chay CH, Walko CM (2012). Investigating the utilization of pharmacokinetic-guided fluorouracil in colorectal cancer. *J Clin Oncol* 30:e13109.
33. Patel JN, Deal AM, O'Neil BH, Ibrahim J, Sherrill GB, Davies JM, Bernard SA, Goldberg RM, Olajide OA, Atluri P, Inzerillo J, McLeod H, Walko C (2013). Application of pharmacokinetic (PK)-guided 5-fluorouracil (FU) in clinical practice. *J Clin Oncol* 31:abstract 2595.
34. Goel G, Chu E, Sun M, Meisner DJ, Lee JJ (2014). Pharmacokinetic (PK) guided optimization of 5-fluorouracil (5-FU) dosing in the treatment of patients with colorectal cancer (CRC). *J Clin Oncol* 32:e14561.

35. Goel G, Sehgal R, Meisner DJ, Sun M, Pasricha G, Chu E, Lee JJ (2015). Therapeutic drug monitoring of 5-fluorouracil (5-FU) in the treatment of patients with colorectal cancer (CRC). *J Clin Oncol* 33:563.
36. Soh IPT, Mogro MJ, Soo RA, Pang A, Tan CS, Chuah B, Zee YK, Wong ALA, Ow SGW, Sundar R, Lim JSJ, Huang Y, Ling WHY, Yong W-P (2015). The optimization of 5-fluorouracil (5FU) dose by pharmacokinetic (PK) monitoring in Asian patients with advanced-stage gastrointestinal (GI) cancer. *J Clin Oncol* 33:770.
37. Kunzmann V, Link K, Miller MC, Holdenrieder S, Bertsch T, Mueller L, Ko Y-D, Stotzer OJ, Suttman I, Braess J, Jaehde U, Roessler M, Moritz B, Kraff S, Fritsch A, Salamone SJ, Wilhelmet M (2015). A prospective, multi-center study of individualized, pharmacokinetically (PK)-guided dosing of 5-fluorouracil (5-FU) in metastatic colorectal cancer (mCRC) patients treated with weekly or biweekly 5-FU/oxaliplatin containing regimens. *J Clin Oncol* 33:3542.
38. Breda M, Baratte S (2010). A review of analytical methods for the determination of 5-fluorouracil in biological matrices. *Anal Bioanal Chem* 397:1191-1201.
39. Beumer JH, Boisdron-Celle M, Clarke W, Courtney JB, Egorin MJ, Gamelin E, Harney RL, Hammett-Stabler C, Lepp S, Li Y, Lundell G, McMillin G, Milano G, Salamone SJ (2009). Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. *Ther Drug Monit* 31:688-694.
40. Vainchtein LD, Rosing H, Schellens JH, Beijnen JH (2010). A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma. *Biomed Chromatogr* 24:374-386.
41. Nakamura M, Makihara K, Onikubo T, Nakamura K, Uchibori K, Azuma S, Murotani K, Iwamoto S, Mishima H (2016). Personalized dose monitoring of fluorouracil and metabolites of capecitabine (XELODA) in colorectal cancer patients (PersonaX). *J Clin Oncol* 34:706.
42. Ploylearmsaeng SA, Fuhr U, Jetter A (2006). How may anticancer chemotherapy with fluorouracil be individualised? *Clin Pharmacokinet* 45:567-592.
43. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB (1987). Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. *Cancer Res* 47:2203-2206.
44. Harris BE, Song R, Soong SJ, Diasio RB (1990). Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels

with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. *Cancer Res* 50:197–201.

45. DiPaolo A, Danesi R, Falcone A, Cionini L, Vannozzi F, Masi G, Allegrini G, Mini E, Bocci G, Conte PF, Del Tacca M (2001). Relationship between 5-fluorouracil disposition, toxicity, and dihydropyrimidine dehydrogenase activity in cancer patients. *Ann Oncol* 12:1301–1306.
46. van Kuilenburg AB, Haasjes J, Richel DJ, Zoetekouw L, Van Lenthe H, De Abreu RA, Maring JG, Vreken P, van Gennip AH (2000). Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. *Clin Cancer Res* 6:4705–4712.
47. Ezzeldin H, Diasio R (2004). Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. *Clin Colorectal Cancer* 4:181–189.
48. Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renée N, Schneider M, Demard F, Milano G (1994). Population study of dihydropyrimidine dehydrogenase in cancer patients. *J Clin Oncol* 12: 2248–2253.
49. Milano G, Etienne MC (1996). Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits. *Ther Drug Monit* 18:335–340.
50. Boisdron-Celle M, Remaud G, Traore S, Poirier AL, Gamelin L, Morel A, Gamelin E (2007.) 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. *Cancer Lett* 249:271–282.
51. Lu Z, Zhang R, Carpenter JT, Diasio RB (1998). Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. *Clin Cancer Res* 4:325–329.
52. Bocci G, Barbara C, Vannozzi F, Di Paolo A, Melosi A, Barsanti G, Allegrini G, Falcone A, Del Tacca M, Danesi R (2006). A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. *Clin Pharmacol Ther* 80:384–395.
53. Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, Schwab M (2013). Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. *Clin Pharmacol Ther* 94:640–645.
54. Henricks LM, Lunenburg CA, Meulendijks D, Gelderblom H, Cats A, Swen

- JJ, Schellens JH, Guchelaar HJ (2015). Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score. *Pharmacogenomics* 16:1277-1286.
55. Capitain O, Boisdron-Celle M, Poirier AL, Abadie-Lacourtoisie S, Morel A, Gamelin E (2008). The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer. *Pharmacogenomics J* 8:256-267.
56. Deenen MJ, Cats A, Sechterberger MK, Severens JL, Smits PHM, Bakker R, Mandigers CM, Soesan M, Beijnen JH, Schellens JHM (2011). Safety, pharmacokinetics (PK), and cost-effectiveness of upfront genotyping of DPYD in fluoropyrimidine therapy. *J Clin Oncol* 29:3606.
57. Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H, Smits PH, Rosing H, Mandigers CM, Soesan M, Beijnen JH, Schellens JH (2016). Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis. *J Clin Oncol* 34:227-234.
58. Sistonen J, Buchel B, Froehlich TK, Kummer D, Fontana S, Joerger M, van Kuilenburg AB, Largiader CR (2014). Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio. *Pharmacogenomics* 15:1653-1666.
59. van Staveren MC, van Kuilenburg ABP, Guchelaar HJ, Meijer J, Punt CJA, de Jong RS, Gelderblom H, Maring JG (2015). Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy. *Br J Clin Pharmacol* 81:553-561.
60. Mattison LK, Ezzeldin H, Carpenter M, Modak A, Johnson MR, Diasio RB (2004). Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-¹³C-uracil breath test. *Clin Cancer Res* 10:2652-2658.
61. Mattison LK, Fourie J, Hirao Y, Koga T, Desmond RA, King JR, Shimizu T, Diasio RB (2006). The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired ¹³CO₂ and plasma [2-¹³C]dihydrouracil. *Clin Cancer Res* 12:549-555.
62. Ezzeldin HH, Acosta EP, Mattison LK, Fourie J, Modak A, Diasio RB (2009). (13)C-5-FU breath test current status and future directions: a comprehensive review. *J Breath Res* 3:047002.
63. Becker R, Hollenbeak CS, Choma A, Kenny P, and S.J. Salamone SJ (2013). Cost-effectiveness of pharmacokinetic dosing of 5-fluorouracil in metastatic colorectal cancer in the United Kingdom. *Value in Health* 16:A139.